KR20020044267A - Cosmetic composition for skin whitening comprising an extract from rubus coreanus miq - Google Patents
Cosmetic composition for skin whitening comprising an extract from rubus coreanus miq Download PDFInfo
- Publication number
- KR20020044267A KR20020044267A KR1020000073267A KR20000073267A KR20020044267A KR 20020044267 A KR20020044267 A KR 20020044267A KR 1020000073267 A KR1020000073267 A KR 1020000073267A KR 20000073267 A KR20000073267 A KR 20000073267A KR 20020044267 A KR20020044267 A KR 20020044267A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- cosmetic composition
- cinnamon
- whitening cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000284 extract Substances 0.000 title claims abstract description 108
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 230000002087 whitening effect Effects 0.000 title claims abstract description 58
- 239000002537 cosmetic Substances 0.000 title claims abstract description 50
- 241001618264 Rubus coreanus Species 0.000 title claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 14
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 14
- 235000006533 astragalus Nutrition 0.000 claims abstract description 13
- 244000024251 Aralia cordata Species 0.000 claims abstract description 3
- 235000014722 Aralia cordata Nutrition 0.000 claims abstract description 3
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 3
- 241000606434 Babylonia Species 0.000 claims abstract description 3
- 235000002428 Cinnamomum japonicum Nutrition 0.000 claims abstract description 3
- 241001350919 Cinnamomum loureiroi Species 0.000 claims abstract description 3
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 3
- 235000007354 Coix lacryma jobi Nutrition 0.000 claims abstract description 3
- 241000124033 Salix Species 0.000 claims abstract description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000020230 cinnamon extract Nutrition 0.000 claims description 27
- 231100000614 poison Toxicity 0.000 claims description 27
- 235000019206 astragalus extract Nutrition 0.000 claims description 21
- 239000012676 herbal extract Substances 0.000 claims description 20
- 229940119485 safflower extract Drugs 0.000 claims description 19
- 230000007096 poisonous effect Effects 0.000 claims description 15
- 235000017803 cinnamon Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000002574 poison Substances 0.000 claims description 12
- 241001061264 Astragalus Species 0.000 claims description 10
- 210000004233 talus Anatomy 0.000 claims description 10
- 235000011399 aloe vera Nutrition 0.000 claims description 9
- 244000144927 Aloe barbadensis Species 0.000 claims description 5
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 5
- 235000014104 aloe vera supplement Nutrition 0.000 claims description 5
- 239000002435 venom Substances 0.000 claims description 4
- 210000001048 venom Anatomy 0.000 claims description 4
- 231100000611 venom Toxicity 0.000 claims description 4
- 244000167125 Cinnamomum japonicum Species 0.000 claims description 2
- 241000723347 Cinnamomum Species 0.000 claims 3
- 241000207199 Citrus Species 0.000 claims 1
- 235000020971 citrus fruits Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 208000003351 Melanosis Diseases 0.000 abstract description 7
- 241000252804 Cinnamomum insularimontanum Species 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 27
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 239000006071 cream Substances 0.000 description 11
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229940124595 oriental medicine Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 206010014970 Ephelides Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 241001116389 Aloe Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- MKMCJLMBVKHUMS-UHFFFAOYSA-N Coixol Chemical compound COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- -1 sulfure Chemical compound 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 description 2
- DPQCZNIGGNJGTD-UHFFFAOYSA-N Chloride-(??)-2-Methylpentanoic acid Natural products CCCCCCC=CCCCCCCCCCC(=O)OC(C)C(C)OC(=O)CCCCCCCC=CCCCCCC DPQCZNIGGNJGTD-UHFFFAOYSA-N 0.000 description 2
- DPQCZNIGGNJGTD-MVCBGFDASA-N Coixenolide Chemical compound CCCCCC\C=C\CCCCCCCCCC(=O)O[C@@H](C)[C@@H](C)OC(=O)CCCCCCC\C=C/CCCCCC DPQCZNIGGNJGTD-MVCBGFDASA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- BJBUTJQYZDYRMJ-UHFFFAOYSA-N Kaempferol 3,7-dimethyl ether Chemical compound C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C=C1 BJBUTJQYZDYRMJ-UHFFFAOYSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- CPUHNROBVJNNPW-UHFFFAOYSA-N aloin A Natural products OC1C(O)C(O)C(CO)OC1OC1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-UHFFFAOYSA-N 0.000 description 2
- AFHJQYHRLPMKHU-WEZNYRQKSA-N aloin B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-WEZNYRQKSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 2
- 229940043234 carbomer-940 Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- VKHHGZYZUVIFCI-UHFFFAOYSA-N 4-(5,6-dimethoxy-3,4-dihydro-2h-chromen-3-yl)benzene-1,3-diol Chemical compound C1C2=C(OC)C(OC)=CC=C2OCC1C1=CC=C(O)C=C1O VKHHGZYZUVIFCI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000002529 Muntingia calabura Species 0.000 description 1
- 235000003886 Muntingia calabura Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 244000020191 Salix babylonica Species 0.000 description 1
- 235000002493 Salix babylonica Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 208000031066 hyperpigmentation of the skin Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- NIKHGUQULKYIGE-LFVVLLIQSA-N isocunabic acid Chemical compound C([C@]1(CC2=C)CC3)C2CC[C@H]1[C@@]1(C)[C@H]3[C@@](C)(C(O)=O)CCC1 NIKHGUQULKYIGE-LFVVLLIQSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NIKHGUQULKYIGE-UHFFFAOYSA-N kaurenoic acid Natural products C1CC2(CC3=C)CC3CCC2C2(C)C1C(C)(C(O)=O)CCC2 NIKHGUQULKYIGE-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- PIUVNPNBPWVVKZ-UHFFFAOYSA-N octadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC PIUVNPNBPWVVKZ-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000003129 oil well Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 231100000332 physical toxicant Toxicity 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229930006696 sabinene Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 복분자 추출물을 포함하는 화장료 조성물에 관한 것으로, 보다 상세하게는 복분자 추출물을 유효성분으로 하고, 독활, 황기, 홍화자, 계지, 계피, 유근피, 의이인 및 알로에 베라로 이루어진 그룹으로부터 선택된 하나 이상의 생약 추출물이 임의로 배합된 복합 생약 추출물들로 이루어진 피부 미백 기능을 극대화시킨 조성물에 관한 것이다.The present invention relates to a cosmetic composition comprising a bokbunja extract, and more particularly, at least one herbal drug selected from the group consisting of bokbunja extract as an active ingredient, poisonous, Astragalus, safflower, cinnamon, cinnamon, roots of Yui, Euiin and aloe vera The present invention relates to a composition for maximizing skin whitening function consisting of complex herbal extracts in which the extract is arbitrarily combined.
인간의 피부색을 결정하는 색소로는 멜라닌 헤모글로빈, 카로티노이드가 있다. 피부, 모발, 눈의 다양한 색깔이 이들 색소에 의해 결정된다. 피부에 있어 색깔을 결정하는 가장 중요한 색소는 멜라닌이며 멜라닌의 양과 성질 그리고 분포의 정도에 따라 피부색이 결정되어 진다.The pigments that determine human skin color include melanin hemoglobin and carotenoids. The various colors of skin, hair and eyes are determined by these pigments. The most important pigment that determines the color of skin is melanin, and the color of skin depends on the amount, nature and distribution of melanin.
인간에게 있어 피부나 모발의 색소는 햇빛(특히 자외선)의 유해한 영향으로부터 피부나 모발을 보호해 주는 역할을 한다. 예를 들어 색소가 부족한 사람은(병명: 알비노증(Albino disease)) 햇빛에 매우 민감하여 화상을 입기 쉬우며 어린나이에도 피부암 발생 확률이 높다. 단파장의 자외선(290-320nm) 및 발암물질은 피부에서 산소 라디칼을 형성시키는데 이 산소 라디칼이 피부세포를 공격하여 피부를 노화시키는 것으로 알려져 있다.In humans, the pigments in the skin and hair protect the skin and hair from the harmful effects of sunlight (especially ultraviolet rays). For example, people with poor pigmentation (albino disease) are very sensitive to sunlight and are prone to burns. Short wavelength ultraviolet rays (290-320 nm) and carcinogens form oxygen radicals in the skin, which are known to attack skin cells and age the skin.
멜라닌의 주요한 기능은 산소 라디칼을 제거하여 이에 의한 손상으로부터 피부를 보호하는 것이다. 그러므로 멜라닌이 많다는 것은 물리적, 화학적 독성물질로부터 피부를 보호하기 위한 효과적인 대응체계를 가지고 있다는 것을 의미한다.The main function of melanin is to remove oxygen radicals and protect the skin from the damage thereby. Therefore, high levels of melanin mean that it has an effective response system to protect the skin from physical and chemical toxicants.
피부흑화(melanogenesis)는 피부세포내에 있는 멜라닌색소생성세포 (melanocyte)에서 자외선, 에스트로겐, 프로스타글란딘, 및 블레오마이신 등의 요인들에 의해 멜라닌 생성활동이 증가되고 이로 말미암아 만들어진 다량의 멜라닌이 각질형성세포(keratinocyte)로 전달되어 피부표피층(epidermis)에 축적된 결과이다. 기미, 주근깨, 피부염증 후의 피부흑화, 노인성 색소반점 등으로 인한 피부의 과색소침착은 당사자에게 미용상의 불편뿐만 아니라 정신적으로 부정적인 영향을 미쳐 사회활동에 불편을 초래하기도 한다. 이러한 요구도 증가로 인하여 이를 예방 및 개선하기 위한 미백용 화장품, 의약품 등이 시판되고 있다.Melanogenesis is due to factors such as ultraviolet rays, estrogens, prostaglandins, and bleomycin in melanocytes in melanocytes, increasing the melanogenesis. It is delivered to keratinocytes and accumulated in the epidermis. Hyperpigmentation of the skin due to blemishes, freckles, skin darkening after skin inflammation, senile pigment spots, etc. can cause not only cosmetic discomfort but also negative psychological effects on the person, leading to discomfort in social activities. Due to the increased demand, cosmetics and pharmaceutical products for whitening are being marketed to prevent and improve them.
화장품으로서의 미백제의 연구는 최근 10년 미만의 역사를 가지고 있으며, 정서적으로 흰 피부를 선호하는 동양권의 생활수준 향상과 더불어 피부 흑화가 자외선에 의한 피부노화로 인식되면서 그 필요성이 점차 증대되고 있다. 90년도 이후, 아르부틴(arbutin), 코지산(kojic acid), 비타민 C 및 그 유도체 등이 개발되어 이를 함유한 미백화장품이 시판되고 있으나, 실질적인 임상효과는 만족스럽지 못한 실정이며, 과도한 색소침착을 개선하기 위한 의약품으로써 히드로퀴논(hydroquinone), 설퓨레(sulfure), 아젤라 산(azelaic acid), 레티노 산(retinoic acid) 등이 사용되고 있으나 큰 자극성과 독성을 갖고 있다.The research of whitening agent as cosmetics has a history of less than 10 years, and the necessity is gradually increasing as skin blackening is recognized as skin aging caused by ultraviolet rays along with the improvement of living standard in the Asian region which prefers emotionally white skin. Since 1990, arbutin, kojic acid, vitamin C and derivatives thereof have been developed and commercialized whitening cosmetics containing them, but the actual clinical effect is not satisfactory and excessive pigmentation As a medicine for improvement, hydroquinone, sulfure, azelaic acid and retinoic acid are used, but they have great irritation and toxicity.
초기의 미백제 개발은 멜라닌 색소생성 과정의 첫 단계인 타이로시나제에 의한 티로신의 산화 억제기능에 초점이 맞추어져 시험관내 실험에서 타이로시나제 활성 억제제를 선별하는 것이 중요한 미백제 개발수단이었다. 특히 사용되는 타이로시나제는 버섯에서 유래된 것으로 사람의 것과는 유사성에 있어서 많은 차이가 있고 여기서 선별된 미백제를 실제 인체에 적용할 경우 피부투과, 세포독성의 문제나 제형내에서의 안정성 등에 문제가 있어 실질적인 임상효과로는 부족한 면이 있으나 이 과정에서 찾아낸 아르부틴, 코지산, 비타민 C 등이 현재까지도 폭넓게 사용되고 있다.The initial development of whitening agents focused on the antioxidant activity of tyrosine by tyrosinase, the first step in the melanin pigmentation process, so screening tyrosinase activity inhibitors in vitro was an important developmental tool. In particular, the tyrosinase used is derived from mushrooms, and there are many differences in similarity to humans. If the selected whitening agent is applied to the human body, there are problems such as skin penetration, cytotoxicity, and stability in the formulation. There is a lack of practical clinical effects, but arbutin, kojic acid, and vitamin C found in this process are still widely used.
최근에는 독성이 상대적으로 적고 자연친화적인 미백화장품을 개발하기 위하여 미백작용을 갖는 식물에 대한 탐색과정을 거쳐 수종의 식물들이 미백에 효과적이라는 사실이 밝혀지고 있다. 그 예로서, 한국특허공고 번호 제 1991-8660호에는 닥나무 추출물을 함유한 미백화장료가 공개되었고, 한국특허공고번호 제 1991-11645호에는 호장근 추출물을 함유한 미백화장료가 공개되었으며, 한국특허공고번호 제 1993-8377호에는 고로쇠나무 추출물을 함유한 미백조성물이 공개되었고, 한국특허공고번호 제 1993-28783호에는 백피 추출물을 함유한 미백조성물 등이 공개되었으나, 현재까지 복분자 추출물을 유효성분으로 한 조성물의 미백효과에 대해서는 알려진 바가 없다.Recently, in order to develop a whitening cosmetics having relatively low toxicity and nature-friendly cosmetics, it has been found that several plants are effective for whitening. As an example, Korean Patent Publication No. 1991-8660 discloses a whitening cosmetic material containing a mulberry extract, and Korean Patent Publication No. 1991-11645 discloses a whitening cosmetic containing a extract of Hojang-geun. No. 1993-8377 discloses a whitening composition containing an extract of Cypress, and in Korea Patent Publication No. 1993-28783, a whitening composition containing an extract of white skin is disclosed, but until now the extract of Bokbunja as an active ingredient There is no known whitening effect of the composition.
본 발명자는 여러 가지 식물들을 대상으로 하여 미백효과를 실험한 결과, 탁월한 미백효과를 나타내는 복분자 추출물의 효능을 발견하고 나아가 독활, 황기, 홍화자, 계지, 계피, 유근피, 의이인 및 알로에 베라 등의 추출물을 배합한 결과, 동등 내지 보다 탁월한 미백 효능을 나타냄을 발견하고 이를 확인하였다.As a result of experimenting on the whitening effect of various plants, the inventors have found the efficacy of the extract of Bokbunja, which shows the excellent whitening effect. As a result of the formulation, it was found to show equivalent to more excellent whitening efficacy and confirmed it.
본 발명의 목적은 복분자 추출물을 유효성분으로 한 미백효과가 탁월한 화장품용 조성물을 제공하는 것이다.An object of the present invention is to provide a cosmetic composition excellent in whitening effect using the bokbunja extract as an active ingredient.
본 발명의 또다른 발명의 목적은 황기 추출물을 유효성분으로 한 미백효과가 탁월한 화장품용 조성물을 제공하는 것이다.It is another object of the present invention to provide a cosmetic composition excellent in whitening effect using the extract as an active ingredient.
본 발명의 또다른 발명의 목적은 홍화자 추출물을 유효성분으로 한 미백효과가 탁월한 화장품용 조성물을 제공하는 것이다.It is another object of the present invention to provide a cosmetic composition excellent in whitening effect using safflower extract as an active ingredient.
본 발명의 또다른 발명의 목적은 계지 추출물을 유효성분으로 한 미백효과가 탁월한 화장품용 조성물을 제공하는 것이다.Another object of the present invention is to provide a cosmetic composition excellent in whitening effect using the extract as an active ingredient.
본 발명의 또다른 발명의 목적은 계피 추출물을 유효성분으로 한 미백효과가 탁월한 화장품용 조성물을 제공하는 것이다.Another object of the present invention is to provide a cosmetic composition excellent in whitening effect using the cinnamon extract as an active ingredient.
본 발명의 또다른 발명의 목적은 유근피 추출물을 유효성분으로 한 미백효과가 탁월한 화장품용 조성물을 제공하는 것이다.It is another object of the present invention to provide a cosmetic composition excellent in whitening effect using the root extract as an active ingredient.
본 발명의 또다른 목적은 복분자 추출물에 독활, 황기, 홍화자, 계지, 계피, 유근피, 의이인 및 알로에 베라로 이루어진 그룹으로부터 선택된 하나 이상의 생약 추출물이 배합된 복합 생약 추출물을 유효성분으로 하는 미백 화장료 조성물을 제공하는 것이다.Still another object of the present invention is to provide a whitening cosmetic composition comprising a compound herbal extract comprising one or more herbal extracts selected from the group consisting of venom, astragalus, safflower, cinnamon, cinnamon, root root, uiyiin and aloe vera in bokbunja extract To provide.
본 발명의 또다른 목적은 복분자 추출물 50 내지 70 중량% 및 독활 추출물 30 내지 50 중량%로 이루어진 미백 화장료 조성물을 제공하는 것이다.Another object of the present invention is to provide a whitening cosmetic composition consisting of 50 to 70% by weight bokbunja extract and 30 to 50% by weight poison extract.
본 발명의 또다른 목적은 복분자 추출물 45 내지 60 중량%, 독활 추출물 30 내지 35 중량% 및 황기 추출물 5 내지 15 중량%로 이루어진 미백 화장료 조성물을 제공하는 것이다.Still another object of the present invention is to provide a whitening cosmetic composition consisting of 45 to 60% by weight of bokbunja extract, 30 to 35% by weight of poisonous extract and 5 to 15% by weight of Astragalus extract.
본 발명의 또다른 목적은 복분자 추출물 40 내지 45 중량%, 독활 추출물 25 내지 30 중량%, 황기 추출물 10 내지 15 중량% 및 홍화자 추출물 15 내지 20중량%로 이루어진 미백 화장료 조성물을 제공하는 것이다.Still another object of the present invention is to provide a whitening cosmetic composition consisting of 40 to 45% by weight of bokbunja extract, 25 to 30% by weight of poisonous extract, 10 to 15% by weight of Astragalus extract and 15 to 20% by weight of safflower extract.
본 발명의 또다른 목적은 복분자 추출물 25 내지 30 중량%, 독활 추출물 15 내지 20 중량%, 황기 추출물 5 내지 10 중량%, 홍화자 추출물 10 내지 15중량% 및 계지 추출물 30 내지 35 중량%로 이루어진 미백 화장료 조성물을 제공하는 것이다.Another object of the present invention is a whitening cosmetic composition consisting of 25 to 30% by weight of bokbunja extract, 15 to 20% by weight of poisonous extract, 5 to 10% by weight of Astragalus extract, 10 to 15% by weight of safflower extract and 30 to 35% by weight of cinnamon extract It is to provide a composition.
본 발명의 또다른 목적은 복분자 추출물 15 내지 20 중량%, 독활 추출물 10 내지 15 중량%, 황기 추출물 2 내지 6 중량%, 홍화자 추출물 5 내지 10 중량%, 계지 추출물 18 내지 23 중량% 및 계피 추출물 35 내지 40 중량%로 이루어진 미백 화장료 조성물을 제공하는 것이다.Another object of the present invention is 15 to 20% by weight of Bokbunja extract, 10 to 15% by weight poison extract, 2 to 6% by weight Astragalus extract, 5 to 10% by weight safflower extract, 18 to 23% by weight cinnamon extract and cinnamon extract 35 It is to provide a whitening cosmetic composition consisting of to 40% by weight.
본 발명의 또다른 목적은 복분자 추출물 10 내지 15 중량%, 독활 추출물 5 내지 8 중량%, 황기 추출물 1 내지 4 중량%, 홍화자 추출물 4 내지 7 중량%, 계지 추출물 13 내지 17 중량%, 계피 추출물 25 내지 28 중량% 및 유근피 추출물 25 내지 28 중량%로 이루어진 미백 화장료 조성물을 제공하는 것이다.Another object of the present invention is 10 to 15% by weight bokbunja extract, 5 to 8% by weight poison extract, 1 to 4% by weight Astragalus extract, 4 to 7% by weight safflower extract, 13 to 17% by weight cinnamon extract, cinnamon extract 25 It is to provide a whitening cosmetic composition consisting of to 28 to 28% by weight and 25 to 28% by weight of the root extract.
본 발명의 또다른 목적은 복분자 추출물 10 내지 13 중량%, 독활 추출물 5 내지 8 중량%, 황기 추출물 1 내지 4 중량%, 홍화자 추출물 4 내지 7 중량%, 계지 추출물 13 내지 16 중량%, 계피 추출물 25 내지 27 중량%, 유근피 추출물 25 내지 27 중량% 및 의이인 추출물 5 내지 7중량%로 이루어진 미백 화장료 조성물을 제공하는 것이다.Another object of the present invention is 10 to 13% by weight bokbunja extract, 5 to 8% by weight poison extract, 1 to 4% by weight Astragalus extract, 4 to 7% by weight safflower extract, 13 to 16% by weight cinnamon extract, cinnamon extract 25 It is to provide a whitening cosmetic composition consisting of to 27% by weight, 25 to 27% by weight of the extract of Yukje skin and 5 to 7% by weight of the extract of Euiin.
본 발명의 또다른 목적은 복분자 추출물 10 내지 12 중량%, 독활 추출물 6 내지 8 중량%, 황기 추출물 2 내지 4 중량%, 홍화자 추출물 4 내지 6 중량%, 계지 추출물 13 내지 15 중량%, 계피 추출물 24 내지 26 중량%, 유근피 추출물 24 내지 26 중량%, 의이인 추출물 5 내지 7중량% 및 알로에 베라 추출물 1 내지 3중량%로 이루어진 미백 화장료 조성물을 제공하는 것이다.Another object of the present invention is 10 to 12% by weight bokbunja extract, 6 to 8% by weight poison extract, 2 to 4% by weight Astragalus extract, 4 to 6% by weight safflower extract, 13 to 15% by weight cinnamon extract, cinnamon extract 24 To 26% by weight, Root skin extract 24 to 26% by weight, Euiyi extract 5-7% by weight and Aloe vera extract 1 to 3% by weight to provide a whitening cosmetic composition.
상기 목적에 따라, 미백작용이 우수한 생약을 검색한 결과, 복분자 추출물을 포함하는 화장료 조성물이 탁월한 효능을 가짐을 밝혀내고, 또한 추가로 독활, 황기, 홍화자, 계지, 계피, 유근피, 의이인 및 알로에 베라로 이루어진 그룹으로부터 선택된 하나 이상의 생약 추출물이 임의로 배합된 복합 생약 추출물들로 이루어진 피부 미백 기능을 극대화시킨다는 것을 알게 되어 본 발명을 완성하게 되었다.According to the above purpose, as a result of searching for an excellent whitening medicine, the cosmetic composition comprising the extract of Bokbunja found that the excellent efficacy, and also the poisonous, Astragalus, safflower, cinnamon, cinnamon, root roots, uiyiin and aloe vera One or more herbal extracts selected from the group consisting of maximizing the skin whitening function consisting of a combination of herbal extracts optionally combined to complete the present invention.
복분자(覆盆子)는 복분자딸기(Rubus coreanusMIQ)의 미성숙 씨로서 제주도 및 중남부지방에 분포하며 한방에서는 양위, 유정(遺情), 빈뇨(頻尿), 허로(虛勞)등의 질환 치료에 사용하며, 지금까지는 알려진 성분으로는 카르본 산(CarvoneAcid) 등이 보고된 바 있다.Bokbunja is an immature seed of Rubus coreanus MIQ, distributed in Jeju-do and South-South provinces. In oriental medicine, it is used to treat diseases such as stomach, oil well, urinary tract, and erosion. Until now, known components such as carboxylic acid (CarvoneAcid) have been reported.
독활(獨活)은 땅두릅나무(Aralia cordataTHUNB)의 뿌리 및 근경으로서, 전국의 습지에 분포하며 한방에서는 감기, 두통, 류마티즘 및 신경통 치료에 사용하며, 지금까지 알려진 성분으로는 리모넨(limonene), 사비넨(Sabinene), 카우르-16-엔-19-오익 산(kaur-16-en-19-oic acid) 등의 테르펜 화합물 등이 분리 보고된 바 있다.Toxic activity is the root and rhizome of Aralia cordata THUNB, which is distributed in wetlands nationwide, and is used for the treatment of colds, headaches, rheumatism and neuralgia in oriental medicine. Limonene, Terpene compounds such as sabinene and kaur-16-en-19-oic acid have been reported separately.
황기는 단너삼(Astragalus membranaceusBGE)의 뿌리로서, 양지쪽의 산비탈, 고산 중턱 등에 분포하며 약용식물로 재배되는 식물로서, 한방에서는 자한(自汗), 도한(盜汗) 등의 치료에 사용되며 임상에서는 강심작용, 모세혈관강화 작용, 항균작용 등이 보고되어 있으며, 지금까지 알려진 성분으로는 2',4'-디히드록시-5,6-디메톡시이소플라반과 쿠마타케닌(kumatakenin) 등이 분리보고된 바 있다.Astragalus is the root of Astragalus membranaceus BGE, which is distributed on mountain slopes and hillsides on both sides, and is cultivated as a medicinal plant. It is used for the treatment of Jahan and Dohan in oriental medicine. Actions, capillary potentiation, and antimicrobial activity have been reported, and 2 ', 4'-dihydroxy-5,6-dimethoxyisoflavan and kumatakenin are reported to be known so far. It has been.
홍화자(紅花子)는 잇꽃(Carthamus tinctoriusL.)의 과실로서 이집트 원산으로서 각지에서 재배되고 있으며, 한방에서는 무월경, 어혈통, 사산, 타박상 등의 치료에 사용되어 왔으며, 임상에서는 자궁수축작용, 혈압강하작용, 혈액응고저해작용 등이 보고되었으며 그 함유성분들로는 리놀렌 산, 올레인 산 등이 보고되어 있다.Safflower is a fruit of Carthamus tinctorius L., native to Egypt and cultivated throughout the country. In oriental medicine, it has been used for the treatment of amenorrhea, fish line, stillbirth, and bruises. It has been reported that hypothermia, blood coagulation inhibitory action, and the like components such as linolenic acid, oleic acid.
계지(桂枝)는 육계나무(Cinnamomum loureiriiNEES)의 햇가지로서, 한방에서는 두통, 근육경련 등의 치료에 사용되며, 임상에서는 항균작용, 항바이러스작용, 항이뇨작용 등이 보고되어 있다.Gyeji (桂枝) is a branch of Cinnamomum loureirii NEES, is used in the treatment of headache, muscle spasms, etc. in oriental medicine, and has been reported in the antimicrobial, antiviral, antidiuretic effect.
계피(桂皮)는 생달나무(Cinnamomum japonicumSIEB)의 가지껍질로서 한방에서는 하리복통, 구토 등의 치료에 사용되며 알려진 성분으로는 펠렌드렌, 유게놀 등이 보고되어 있다.Cinnamon is the eggplant bark of Cinnamomum japonicum SIEB, which is used for the treatment of hari abdominal pain, vomiting, etc. in oriental medicine, and known ingredients are phenlene and eugenol.
유근피(柳根皮)는 수양버들(Salix babyloniaL.)의 뿌리와 수염뿌리의 껍질이며, 물가의 습지대에서 재배되며 한방에서는 임질, 황달, 류마티스성 두통, 치통, 화상 등의 치료에 사용되며, 지금까지 알려진 성분으로는 살리신(saicin) 등이 보고된 바 있다.The roots of the weeping willow ( Salix babylonia L.) and the roots of the beard roots are cultivated in waterside wetlands and are used for the treatment of gonorrhea, jaundice, rheumatic headaches, toothaches and burns. As far as known ingredients such as salin (saicin) has been reported.
의이인(薏苡仁)은 율무(Coix lachryma-jobiL.)의 종자로서 한방에서는 설사, 배농, 이습(利濕), 수종(水腫), 각기 등의 치료에 사용되며 임상에서는 항암작용, 혈압강하작용, 자궁수축작용, 장관운동조절작용 등이 보고된 바 있으며 알려진 성분으로는 코익솔(coixol), 코익세놀라이드(coixenolide), 시토스테롤, 스티그마스테롤 등이 분리보고된 바 있다.Euiin (인 仁) is a seed of Yulmu ( Coix lachryma-jobi L.), which is used for the treatment of diarrhea, drainage, diarrhea, water species, and others in oriental medicine. , Uterine contraction, intestinal motility control action has been reported, and known components such as coixol (coixol), coixenolide (coixenolide), cytosterol, stigmasterol and the like have been reported.
알로에 베라(Aloe veraL)는 다년생 초본으로서 아프리카 원산이며 우리나라에서도 재배하고 있는 식물로서, 한방에서는 소아경련, 월경곤란 등의 치료에 사용되며, 임상에서는 사하작용, 상처치료 및 항암작용이 있는 것으로 보고된 바 있으며, 알려진 성분으로는 알로인(aloin), 쿠마린산(coumaric acid) 등이 분리보고된 바 있다. Aloe vera L is a perennial herb and is native to Africa and is also cultivated in Korea. It is used for the treatment of pediatric cramps and dysmenorrhea in oriental medicine, and clinically reported to have hypothalamic, wound healing and anticancer activity. Known components, such as aloin (aloin), coumaric acid (coumaric acid) has been reported separately.
본 발명의 생약 추출물들은 통상적인 방법에 따라 제조될 수 있으며, 예를 들어, 음건 건조하여 세절한 독활을 물 또는 메탄올, 에탄올 등의 저급알콜, 바람직하게는 90% 메탄올을 가하고 5 내지 80℃, 바람직하게는 30 내지 55℃에서 15분 내지 48시간, 바람직하게는 30분 내지 12시간 동안 추출하여 얻을 수 있으며, 복분자, 의이인, 홍화자와 같은 견고한 형태의 생약 추출물은 분쇄기를 이용하여 분쇄 가공하여 상기한 바와 같은 공정을 통하여 그 추출물을 얻을 수 있다.Herbal extracts of the present invention can be prepared according to a conventional method, for example, dry and finely toxic dry water or lower alcohol, preferably 90% methanol, such as methanol, ethanol and 5 to 80 ℃, Preferably it can be obtained by extracting for 15 minutes to 48 hours, preferably 30 minutes to 12 hours at 30 to 55 ℃, the herbal extracts of solid forms such as bokbunja, uiyiin, safflower are ground by a pulverizer The extract can be obtained through the same process.
상기한 추출물 제조방법으로 얻어진 추출물 중에 복분자 추출물은 탁월한 미백효과를 나타내었으며, 추가적으로 독활, 황기, 홍화자, 계지, 계피, 유근피, 의이인 및 알로에 베라 추출물을 배합한 복합 생약 추출물로 실험한 결과 미백기능의 상승효과를 나타냄을 발견하였다.Among the extracts obtained by the above-mentioned extract preparation method, the bokbunja extract showed an excellent whitening effect. It was found to show a synergistic effect.
복합생약 추출물을 사용하는 경우, 이 추출물은 복분자 추출물 50 내지 70 중량% 및 독활 추출물 30 내지 50 중량%; 또는 복분자 추출물 45 내지 60 중량%, 독활 추출물 30 내지 35 중량% 및 황기 추출물 5 내지 15 중량%; 또는 복분자 추출물 40 내지 45 중량%, 독활 추출물 25 내지 30 중량%, 황기 추출물 10 내지 15 중량% 및 홍화자 추출물 15 내지 20중량%; 또는 복분자 추출물 25 내지 30 중량%, 독활 추출물 15 내지 20 중량%, 황기 추출물 5 내지 10 중량%, 홍화자 추출물 10 내지 15중량% 및 계지 추출물 30 내지 35 중량%; 또는 복분자 추출물 15 내지 20 중량%, 독활 추출물 10 내지 15 중량%, 황기 추출물 2 내지 6 중량%, 홍화자 추출물 5 내지 10 중량%, 계지 추출물 18 내지 23 중량% 및 계피 추출물 35 내지 40 중량%; 또는 복분자 추출물 10 내지 15 중량%, 독활 추출물 5 내지 8 중량%, 황기 추출물 1 내지 4 중량%, 홍화자 추출물 4 내지 7 중량%, 계지 추출물 13 내지 17 중량%, 계피 추출물 25 내지 28 중량% 및 유근피 추출물 25 내지 28 중량%; 또는 복분자 추출물 10 내지 13 중량%, 독활 추출물 5 내지 8 중량%, 황기 추출물 1 내지 4 중량%, 홍화자 추출물 4 내지 7 중량%, 계지 추출물 13 내지 16 중량%, 계피 추출물 25 내지 27 중량%, 유근피 추출물 25 내지 27 중량% 및 의이인 추출물 5 내지 7중량%; 또는 복분자 추출물 10 내지 12 중량%, 독활 추출물 6 내지 8 중량%, 황기 추출물 2 내지 4 중량%, 홍화자 추출물 4 내지 6 중량%, 계지 추출물 13 내지 15 중량%, 계피 추출물 24 내지 26 중량%, 유근피 추출물 24 내지 26 중량%, 의이인 추출물 5 내지 7중량% 및 알로에 베라 추출물 1 내지 3중량%로 이루어질 수 있다.When using the herbal extract, the extract is 50 to 70% by weight bokbunja extract and 30 to 50% by weight poison extract; Or 45-60 wt% of Bokbunja extract, 30-35 wt% of venom extract and 5-15 wt% of Astragalus extract; Or 40 to 45% by weight of Bokbunja extract, 25 to 30% by weight of poisonous extract, 10 to 15% by weight of Astragalus extract and 15 to 20% by weight of safflower extract; Or 25-30% by weight of Bokbunja extract, 15-20% by weight of poisonous extract, 5-10% by weight of Astragalus extract, 10-15% by weight of safflower extract and 30-35% by weight of gye extract; Or 15-20 wt% of Bokbunja extract, 10-15 wt% of venom extract, 2-6 wt% of Astragalus extract, 5-10 wt% of safflower extract, 18-23 wt% of cinnamon extract and 35-40 wt% of cinnamon extract; Or 10 to 15% by weight bokbunja extract, 5 to 8% by weight poison extract, 1 to 4% by weight Astragalus extract, 4 to 7% by weight safflower extract, 13 to 17% by weight cinnamon extract, 25 to 28% by weight cinnamon extract 25 to 28 wt% extract; Or 10 to 13% by weight bokbunja extract, 5 to 8% by weight poison extract, 1 to 4% by weight Astragalus extract, 4 to 7% by weight safflower extract, 13 to 16% by weight cinnamon extract, 25 to 27% by weight cinnamon extract 25 to 27% by weight of the extract and 5 to 7% by weight of Euiin extract; Or 10 to 12% by weight bokbunja extract, 6 to 8% by weight poison extract, 2 to 4% by weight Astragalus extract, 4 to 6% by weight safflower extract, 13 to 15% by weight cinnamon extract, 24 to 26% by weight cinnamon extract It may consist of 24 to 26% by weight of the extract, 5 to 7% by weight of Euiyi extract and 1 to 3% by weight of aloe vera extract.
상기와 같은 복분자 추출물 또는 복합 생약 추출물을 통상의 화장품 제조용 기제물질과 혼합하여 미백 화장료 조성물을 제조할 수 있다.A bokbunja extract or a composite herbal extract as described above may be mixed with a conventional cosmetic preparation base material to prepare a whitening cosmetic composition.
본 발명에 있어서, 복분자 단독 또는 독활, 황기, 홍화자, 계지, 계피, 유근피, 의이인 및 알로에 베라 추출물들과의 배합 추출물은 피부 화장료 조성물을 기준으로 0.0001 중량% 내지 20.00 중량 %의 양으로 사용한다. 또한 화장료 조성물을 제조하기 위한 기제물질은 에멀젼 상에서는 정제수, 1가 또는 다가 알콜 지방 및 오일, 계면 활성제 등이고 기타로 착향제 및 착색료, 방부제 등이다. 가용화 상태에서는 정제수, 계면 활성제, 1가 및 다가 알콜 등이며 에멀젼 상과 같이 착향제 및 착색료, 방부제 등을 사용한다.In the present invention, Bokbunja alone or combined extract with Astragalus, Astragalus, Safflower, Cinnamon, Cinnamon, Yugeunpi, Uiin and Aloe Vera extracts is used in an amount of 0.0001% to 20.00% by weight based on the skin cosmetic composition. In addition, the base material for preparing the cosmetic composition is purified water, monohydric or polyhydric alcohol fats and oils, surfactants and the like on the emulsion, and other flavoring agents, coloring agents, preservatives and the like. In the solubilized state, purified water, surfactants, monohydric and polyhydric alcohols, and the like, and flavoring agents, colorants, and preservatives are used as in the emulsion phase.
피부 화장료에서 크림, 로션은 각각 V/O 에멀젼, O/W 에멀젼으로 제조할 수 있고, 이 때 사용되는 유화제의 종류는 음이온 형태, 양이온 형태, 비이온 형태 등으로 구분될 수 있다.In skin cosmetics, creams and lotions may be prepared as V / O emulsions and O / W emulsions, respectively, and the type of emulsifier used may be classified into anionic form, cationic form, and nonionic form.
이하 본 발명을 다음과 같은 실시 예에 의하여 더욱 상세하게 설명하고자 한다. 단, 다음의 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 범위가 이것들만으로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following Examples are only for illustrating the present invention, and the scope of the present invention is not limited to these.
실시예 1 : 복분자 추출물의 제조Example 1 Preparation of Bokbunja Extract
한국 전라도 내장산 일대에서 채집한 복분자 딸기나무의 과육으로부터 분리한 복분자 500g을 음건하여 쇠절구로 분쇄한 후, 90% 에탄올 500ml를 넣고 환류장치를 통하여 얻어진 90% 에탄올 추출물을 동결건조하여 건조물 18g을 얻었다.500 g of bokbunja isolated from the flesh of the bokbunja strawberry tree collected from Naejangsan, Korea, was crushed with iron mortar, and then 500% of 90% ethanol was added and lyophilized 90% ethanol extract obtained through the reflux apparatus to obtain 18 g of dried product. .
실시예 2 : 독활 추출물의 제조Example 2 Preparation of Toxic Extract
서울 종암동 경동시장에서 건조상태로 구입한 독활 500g을 세절한 후, 이를 90% 에탄올 500ml를 넣고 환류장치를 통하여 얻은 90% 에탄올 추출물을 동결건조하여 건조물 25g을 얻었다.After 500 g of the poisonous toxin purchased in the Gyeongdong market, Jongam-dong, Seoul was chopped, 500 ml of 90% ethanol was added thereto and 90 g of the ethanol extract obtained through the reflux apparatus was lyophilized to obtain 25 g of the dried product.
실시예 3 : 알로에 베라 추출물의 제조Example 3 Preparation of Aloe Vera Extract
서울 종암동 경동시장에서 구입한 알로에 1 kg을 겉껍질을 칼로 벗겨 내고 줄기 속에 있는 무색 투명한 겔상태의 알로에를 물 500ml를 넣고 환류장치를 통하여 얻은 물 추출물을 동결건조 건조물 30g을 얻었다.1 kg of aloe purchased at Gyeongdong Market, Seoul, Korea was peeled off with a knife, 500 ml of colorless transparent gel aloe in the stem was put in water, and the water extract obtained through the reflux device was obtained by drying the freeze-dried dried product 30 g.
실시예 4 내지 7: 실시예 2에 기재된 독활 추출물의 추출방법으로 얻어진 유근피, 황기, 계지, 계피 추출물을 각각 동결건조시켜 건조물 23, 20, 20, 23g 씩을 얻었다. Examples 4-7 : The roots of the roots of the root extract, Astragalus, Cinnamon and Cinnamon obtained by the extraction method of the poisonous extract described in Example 2 were lyophilized to obtain dried products 23, 20, 20 and 23 g each.
실시예 8 내지 9: 실시예 1에 기재된 복분자 추출물의 추출방법으로 얻은 의이인 및 홍화자 추출물을 각각 동결건조하여 건조물 21 및 20g을 얻었다. Examples 8 to 9 : Uyiinin and safflower extracts obtained by the extracting method of Bokbunja extract described in Example 1 were lyophilized to obtain dried products 21 and 20g.
실시예 10 내지 17: 하기 표 1에 기재된 바와 같이 각 생약 추출 건조물들을 배합하였다. Examples 10-17 : Each herbal extract dried was combined as described in Table 1 below.
실시예 18: 크림 1의 제조 Example 18 Preparation of Cream 1
크림은 다음의 조성에 따른다.Cream is based on the following composition.
이 크림을 제조하기 위하여 글리세릴 모노스테아레이트, 보존제인 퍼하이드로스쿠알렌 및 정제수를 포함하는 수용상을 80℃로 가열하고; 여기에 카르보머 940을 분산시키고; 이것을 트리에탄올아민으로 중화시켰다. 80℃로 가열하여 균질화시킨, 나머지 지질상들 성분들을 격렬하게 교반시키면서 상기 중화된 수용상에 가하였다. 실시예 1의 건조물을 물 10g에 분산시키고 40℃하에서 교반하면서 크림에투입하였다. 혼합물을 상온으로 냉각시켰다.To prepare this cream, an aqueous phase comprising glyceryl monostearate, perhydrosqualene as a preservative, and purified water was heated to 80 ° C; Dispersing carbomer 940 therein; This was neutralized with triethanolamine. The remaining lipid phase components, heated to 80 ° C. and homogenized, were added to the neutralized aqueous phase with vigorous stirring. The dried product of Example 1 was dispersed in 10 g of water and poured into cream with stirring at 40 ° C. The mixture was cooled to room temperature.
실시예 19 내지 26: 크림 2 내지 9의 제조 Examples 19-26 Preparation of Creams 2-9
실시예 10내지 17로부터 얻어진 건조 배합물들을 실시예 18의 크림 1의 실시예1의 건조물을 대체한 것을 제외하고는 실시예 18과 동일한 방법으로 크림 2 내지 9를 제조하였다.Creams 2 to 9 were prepared in the same manner as in Example 18, except that the dry blends obtained from Examples 10 to 17 were substituted for the dry matter of Example 1 of Cream 1 of Example 18.
실시예 27: 미백효과의 확인 Example 27 Confirmation of Whitening Effect
본 실시예에는 건강한 자원자들을 대상으로 본 크림제들을 사용한 후에 나타난 미백효과를 확인한 것이다.In this example, the whitening effect appeared after using the creams for healthy volunteers.
a) 한정선 (여자)a) Limited Line (Female)
거주지 : 대구Residence: Daegu
사용방법: 매일 1회씩 36일간 연속 사용How to use: 36 consecutive days once daily
효 과effect
10일 정도 후에 눈에 띄게 기미, 주근깨가 옅어졌고 화장을 한 후에는 약간의 트러블이 생겼다가 곧 사라졌다. 얼굴색이 어둡고 검은 편이었는데 많이 밝아지고 원래의 피부색으로 돌아 간 것같다.After about 10 days, the spots and freckles became noticeably pale, and after makeup, some troubles appeared and disappeared. The face color was dark and black, but it became much brighter and went back to the original skin color.
b) 송기웅씨 부인 (여자)b) Mrs. Song Ki-woong (Female)
거주지 : 서울 상계동Residence: Sanggye-dong, Seoul
사용방법: 매일 1회씩 취침전 얼굴에 팩을 하고 한두시간 뒤에 본 크림제로 지우는 크린싱 크림같이 사용하였음.How to use: Pack face to face once a day before bed and use as a cleansing cream to remove with this cream one or two hours later.
효 과effect
7일 정도 후에 얼굴이 뽀얗게 변하고 깨끗해짐.After 7 days your face will turn white and clear.
c) 박단심 (여자)c) Park Dan Sim (Female)
효 과effect
얼굴에 기미가 생겨 발랐는데 기미가 거의 없어짐.I have a blemish on my face and almost no blemish on it.
d) 장미경 (여자)d) roses (women)
효 과effect
막내 동생에게 권했는데 2주째 얼굴이 깨끗해지고 뽀얗게 됨.I recommended it to my youngest brother, and her face became clean and white for two weeks.
e) 박민정 (여자)e) Park Min Jung (Female)
거주지 : 삼천포Residence: Samcheonpo
효 과effect
주근깨가 있어 10일정도 발랐는데 주근깨가 거의 보이지 않음.I had freckles and applied it for 10 days, but there was almost no freckles.
f) 고옥님 (여자)f) Go Ok (Female)
거주지 : 전남 담양Residence: Damyang, Jeonnam
효 과effect
1개월 사용으로 기미가 엷어지고 피부가 맑아졌음.After one month of use, the skin became thinner and the skin became clearer.
복분자 단독 또는 독활, 유근피, 황기, 홍화자, 계지, 계피, 의이인 및 알로에 추출물들과의 배합 추출물은 효과적으로 미백활성을 나타내어 피부의 기미 또는 주근깨 예방 및 치료에 유용하다.Bokbunja alone or poisonous extract, Yugeun skin, Astragalus, Safflower, Cinnamon, Cinnamon, Uyiin and aloe extracts extracts effectively exhibit whitening activity and are useful for preventing and treating freckles or freckles of the skin.
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000073267A KR20020044267A (en) | 2000-12-05 | 2000-12-05 | Cosmetic composition for skin whitening comprising an extract from rubus coreanus miq |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020000073267A KR20020044267A (en) | 2000-12-05 | 2000-12-05 | Cosmetic composition for skin whitening comprising an extract from rubus coreanus miq |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20020044267A true KR20020044267A (en) | 2002-06-15 |
Family
ID=27679583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020000073267A Ceased KR20020044267A (en) | 2000-12-05 | 2000-12-05 | Cosmetic composition for skin whitening comprising an extract from rubus coreanus miq |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20020044267A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100406124B1 (en) * | 2001-03-30 | 2003-11-15 | 주식회사 태평양 | Skin whitening cosmetic formulations co-containing melanogenesis inhibitors and UV B irradiation- induced prostaglandin synthesis inhibitors in skin cells |
KR100654959B1 (en) * | 2005-03-29 | 2006-12-06 | (주)케비젠 | Whitening cosmetic composition |
KR100699333B1 (en) * | 2005-01-19 | 2007-03-26 | 김원용 | Antimicrobial composition containing root extract of bokbunja or raspberries |
KR100829720B1 (en) * | 2006-08-30 | 2008-05-15 | 주식회사 코리아나화장품 | Convergent cosmetic composition containing Bokbunja extract as an active ingredient |
KR100937187B1 (en) * | 2007-12-18 | 2010-01-19 | 전라북도 고창군 | Manufacturing method of functional cosmetics from residue after manufacturing bokbunjaju |
KR20200056819A (en) * | 2018-11-15 | 2020-05-25 | 김영배 | Composition for improving skin barrier function comprising rubus coreanus miquel oil |
KR20210066030A (en) * | 2009-08-26 | 2021-06-04 | 마리 케이 인코포레이티드 | Topical skin care formulations comprising plant extracts |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61263905A (en) * | 1985-05-17 | 1986-11-21 | Pola Chem Ind Inc | Cosmetic |
JPS6357510A (en) * | 1986-08-27 | 1988-03-12 | Shiseido Co Ltd | Cosmetic |
KR900013932A (en) * | 1989-03-22 | 1990-10-22 | 박효철 | Herbal Herbal Ingredients for Cosmetic Powders and Extracts |
KR930021192A (en) * | 1992-04-11 | 1993-11-22 | 이형주 | Herbal lotion containing herbal medicine and its manufacturing method |
KR970061238A (en) * | 1996-02-01 | 1997-09-12 | 이동빈 | Herbal medicine herbal powder massage supplies |
US5843911A (en) * | 1995-02-10 | 1998-12-01 | Suntory Limited | Hyaluronidase inhibitor containing god-type ellagitannin as active ingredient |
JPH11116430A (en) * | 1997-10-13 | 1999-04-27 | Chemical Pro Cosmetic:Kk | Skin and hair cosmetic and its production |
KR20010038100A (en) * | 1999-10-22 | 2001-05-15 | 서경배 | Cosmetic compositions for skin whitening containing extract of galenical medicines |
-
2000
- 2000-12-05 KR KR1020000073267A patent/KR20020044267A/en not_active Ceased
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61263905A (en) * | 1985-05-17 | 1986-11-21 | Pola Chem Ind Inc | Cosmetic |
JPS6357510A (en) * | 1986-08-27 | 1988-03-12 | Shiseido Co Ltd | Cosmetic |
KR900013932A (en) * | 1989-03-22 | 1990-10-22 | 박효철 | Herbal Herbal Ingredients for Cosmetic Powders and Extracts |
KR930021192A (en) * | 1992-04-11 | 1993-11-22 | 이형주 | Herbal lotion containing herbal medicine and its manufacturing method |
US5843911A (en) * | 1995-02-10 | 1998-12-01 | Suntory Limited | Hyaluronidase inhibitor containing god-type ellagitannin as active ingredient |
KR970061238A (en) * | 1996-02-01 | 1997-09-12 | 이동빈 | Herbal medicine herbal powder massage supplies |
JPH11116430A (en) * | 1997-10-13 | 1999-04-27 | Chemical Pro Cosmetic:Kk | Skin and hair cosmetic and its production |
KR20010038100A (en) * | 1999-10-22 | 2001-05-15 | 서경배 | Cosmetic compositions for skin whitening containing extract of galenical medicines |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100406124B1 (en) * | 2001-03-30 | 2003-11-15 | 주식회사 태평양 | Skin whitening cosmetic formulations co-containing melanogenesis inhibitors and UV B irradiation- induced prostaglandin synthesis inhibitors in skin cells |
KR100699333B1 (en) * | 2005-01-19 | 2007-03-26 | 김원용 | Antimicrobial composition containing root extract of bokbunja or raspberries |
KR100654959B1 (en) * | 2005-03-29 | 2006-12-06 | (주)케비젠 | Whitening cosmetic composition |
KR100829720B1 (en) * | 2006-08-30 | 2008-05-15 | 주식회사 코리아나화장품 | Convergent cosmetic composition containing Bokbunja extract as an active ingredient |
KR100937187B1 (en) * | 2007-12-18 | 2010-01-19 | 전라북도 고창군 | Manufacturing method of functional cosmetics from residue after manufacturing bokbunjaju |
KR20210066030A (en) * | 2009-08-26 | 2021-06-04 | 마리 케이 인코포레이티드 | Topical skin care formulations comprising plant extracts |
KR20200056819A (en) * | 2018-11-15 | 2020-05-25 | 김영배 | Composition for improving skin barrier function comprising rubus coreanus miquel oil |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5476651A (en) | Cosmetic or pharmaceutical composition, especially dermatological composition, intended for promoting the pigmentation of the skin or hair, containing an extract of cyperus, and the process for its manufacture | |
JP3499616B2 (en) | Application to hydroxytyrosol, melanin production inhibitor or lipid peroxide production inhibitor | |
JP3415199B2 (en) | External preparation for skin | |
CA2644045A1 (en) | Combination or plant extract comprising verbascoside and luteolin and their use in a cosmetically or pharmaceutical composition for pigmentation modulation | |
JP3407935B2 (en) | External preparation for skin | |
KR100564108B1 (en) | Cosmetic composition containing a mixed plant extract having an anti-aging effect | |
US5869031A (en) | Depigmenting dermatological and/or cosmetic composition | |
KR20100042181A (en) | Cosmetic compositions containing extract of rheum undulatum and coptidis rhizoma for skin-protection against uv | |
KR20090017282A (en) | Cosmetic composition containing herbal herbal medicine extract with antioxidant effect | |
KR102343166B1 (en) | Cosmetic composition having anti-oxidant, anti-inflammatory, skin soothing, regeneration, elasticity and moisturizing effects which comprise Melaleuca Alternifolia (Tea Tree) Leaf, Artemisia Princeps Leaf, Polygonum Fagopyrum (Buckwheat) Seed and Capryloyl Salicylic Acid | |
JP2002308750A (en) | Skin care preparation | |
JPH09227353A (en) | Whitening cosmetic composition | |
KR101009766B1 (en) | Cosmetic composition for anti-wrinkle containing haechocho extract and japonica wormwood extract | |
KR20020044267A (en) | Cosmetic composition for skin whitening comprising an extract from rubus coreanus miq | |
KR940001125B1 (en) | Tyrosinase Inhibitor Composition Containing Chrysanthemum Extract | |
KR100357416B1 (en) | Compositions of whitening cosmetics containing special herbal extracts | |
BR102014025813A2 (en) | compositions comprising paulownia tomentosa wood extracts and uses thereof | |
KR102226179B1 (en) | Cosmetic Compositions for Anti-aging Comprising Extracts of Plants | |
KR101252560B1 (en) | Cosmetic composition containing extracts of Impatiens balsamina L. for controlling anti-acne or anti-comedone | |
KR20080001031A (en) | Cosmetic composition for anti-wrinkle containing hawthorn extract | |
KR100564107B1 (en) | Cosmetic composition containing mixed plant extract having anti-aging effect | |
KR20200129888A (en) | Cosmetic composition containing black kelp | |
KR100593511B1 (en) | Anti acne cosmetics using natural products | |
KR101083029B1 (en) | UV-absorbing cosmetic composition containing rice-derived embryo and rhubarb extract | |
KR100500642B1 (en) | Whitening containing extract from Anthriscus sylvestris or Lepidium apetalum Wild. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20001205 |
|
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20011127 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20001205 Comment text: Patent Application |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040329 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20040708 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20040329 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |